<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-title>Journal of Translational Medicine</journal-title><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15659244</article-id><article-id pub-id-type="pmc">PMC546233</article-id><article-id pub-id-type="publisher-id">1479-5876-3-3</article-id><article-id pub-id-type="doi">10.1186/1479-5876-3-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>T cell responses against tumor associated antigens and prognosis in colorectal cancer patients</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Nagorsen</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dirk.nagorsen@charite.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Scheibenbogen</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>carmen.scheibenbogen@charite.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Letsch</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anne.letsch@charite.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Germer</surname><given-names>Christoph-Thomas</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>germer@klinikum-nuernberg.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Buhr</surname><given-names>Heinz-Johannes</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>heinz.buhr@charite.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Hegewisch-Becker</surname><given-names>Susanna</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>s.hegewisch-becker@uke.uni-hamburg.de</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Rivoltini</surname><given-names>Licia</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>rivoltini@istitutotumori.mi.it</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Thiel</surname><given-names>Eckhard</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>eckhard.thiel@charite.de</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Keilholz</surname><given-names>Ulrich</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ulrich.keilholz@charite.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Medical Department III, Hematology, Oncology, and Transfusion Medicine, Charit&#x000e9; University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany</aff><aff id="I2"><label>2</label>Department of Surgery, Charit&#x000e9; University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany</aff><aff id="I3"><label>3</label>Department of Oncology and Hematology, University Clinic Eppendorf, Hamburg, Germany</aff><aff id="I4"><label>4</label>Istituto Nazionale Tumori, Milan, Italy</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>19</day><month>1</month><year>2005</year></pub-date><volume>3</volume><fpage>3</fpage><lpage>3</lpage><ext-link ext-link-type="uri" xlink:href="http://www.translational-medicine.com/content/3/1/3"/><history><date date-type="received"><day>22</day><month>11</month><year>2004</year></date><date date-type="accepted"><day>19</day><month>1</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Nagorsen et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Nagorsen et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Nagorsen
               Dirk
               
               dirk.nagorsen@charite.de
            </dc:author><dc:title>
            T cell responses against tumor associated antigens and prognosis in colorectal cancer patients
         </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>Journal of Translational Medicine 3(1): 3-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1479-5876(2005)3:1&#x0003c;3&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1479-5876</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Introduction</title><p>Spontaneous T cell responses against specific tumor-associated antigens (TAA) are frequently detected in peripheral blood of tumor patients of various histiotypes. However, little is known about whether these circulating, spontaneously occurring, TAA-reactive T cells influence the clinical course of disease.</p></sec><sec sec-type="methods"><title>Methods</title><p>Fifty-four HLA-A2 positive colorectal cancer patients had been analyzed for the presence of T cell responses against epitopes derived from the TAA Ep-CAM, her-2/<italic>neu</italic>, and CEA either by ELISPOT assay or by intracellular cytokine staining. Then, Kaplan-Meier survival analysis was performed comparing T-cell-responders and T-cell-non-responders. For comparison, a group of T-cell-non-responders was compiled stringently matched to T-cell-responders based on clinical criteria and also analyzed for survival.</p></sec><sec><title>Results</title><p>Sixteen out of 54 patients had a detectable T cell response against at least one of the three tested TAA. Two out of 21 patients (9.5%) with limited stage of disease (UICC I and II) and 14 out of 33 patients (42.4%) with advanced disease (UICC III and IV) were T cell response positive. Comparing all T-cell-responders (n = 16) and all T-cell-non-responders (n = 38), no survival difference was found. In an attempt to reduce the influence of confounding clinical factors, we then compared 16 responders and 16 non-responders in a matched group survival analysis; and again no survival difference was found (p = 0.7).</p></sec><sec><title>Conclusion</title><p>In summary, we found no evidence that spontaneous peripheral T cell responses against HLA-A2-binding epitopes of CEA, her-2/neu and Ep-CAM are a strong prognostic factor for survival.</p></sec></abstract><kwd-group><kwd>T cell response</kwd><kwd>antigen</kwd><kwd>colorectal cancer</kwd><kwd>survival</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The importance of the immune system in containing tumor growth is supported by animal studies and various observations in humans [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. These include increased prevalence of certain tumors following immunosuppression as well as the demonstration, that the presence of intralesional T cells is correlated with improved clinical outcome in various solid tumors [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. In particular in CRC, the presence of CD8+ T cells within the tumor microenvironment was significantly associated with a better survival in several studies [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. However, the antigen-specificity of these cells was not determined. T cell responses against specific tumor-associated antigens (TAA) are frequently detected in the peripheral blood of tumor patients [reviewed in [<xref ref-type="bibr" rid="B10">10</xref>]] of various histiotypes including colorectal cancer [<xref ref-type="bibr" rid="B11">11</xref>], melanoma [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>], acute myeloid leukemia [<xref ref-type="bibr" rid="B14">14</xref>], breast cancer [<xref ref-type="bibr" rid="B15">15</xref>], neuroblastoma [<xref ref-type="bibr" rid="B16">16</xref>], and head and neck cancer [<xref ref-type="bibr" rid="B17">17</xref>]. Data from selected single patients suggest a favorable clinical course in patients with peripheral, spontaneous TAA-directed T cells [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. However, this type of analysis does not allow firm conclusions. The only study comparing clinical outcome of patients with presence of antigen-specific immune responses including natural as well as vaccine-induced antibodies against melanoma antigen GM2 showed an improved survival in favor of immune responders [<xref ref-type="bibr" rid="B20">20</xref>]. TAA-directed T cell responses can reliably be induced using various vaccination approaches [reviewed in [<xref ref-type="bibr" rid="B21">21</xref>]]. Several recent reports have found a correlation between induction of a TAA-directed T cell response by vaccination and clinical response [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B25">25</xref>]. Preliminary data also suggest a possibly favorable clinical effect of vaccine-induced T cells in adjuvant vaccination [<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B29">29</xref>]. Taken together, these data lead to the question, whether the presence of spontaneous TAA-specific T cells might be a positive prognostic factor. So far, however, no study has systematically compared survival data of patients with and without presence of a spontaneous TAA-directed T cell response.</p><p>In previous studies, we have demonstrated spontaneous T cell responses against the TAA CEA, Ep-CAM, or her-2/neu in peripheral blood of approximately 25% of colorectal cancer patients [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. These cells were identified in functional T cell assays by antigen-induced IFN&#x003b3; production. More detailed analyses in some samples revealed a CD3+ CD8+ IFN&#x003b3;+ CD69+ CD45RA+ phenotype [<xref ref-type="bibr" rid="B11">11</xref>], indicative of an effector T cell subset that is able to directly mediate tumor cell lysis [<xref ref-type="bibr" rid="B19">19</xref>]. Spontaneous TAA-specific T cells with the potential of effector cells should, theoretically, be capable of destroying tumor cells and thereby lead to elimination of residual disease or prevent tumor progression. To investigate whether a peripheral, spontaneous T cell response has an effect on the clinical outcome of tumor patients, we analyzed survival data of CRC patients with a TAA-directed T cell response and compared these data with the clinical course of CRC patients without detectable T cell response.</p></sec><sec><title>Patients, materials, and methods</title><sec><title>Patient selection and T cell assays</title><p>After institutional review board approval and informed consent, peripheral blood mononuclear cells from 132 patients with CRC in all stages of disease had been prospectively collected and frozen for T cell analysis. All analyses have been performed in compliance with the Helsinki Declaration. Fifty-four patients were tested positive for HLA-A2 and were subsequently analyzed for the presence of T cell responses against the HLA-A*0201 presented T cell epitopes Ep-CAM p263&#x02013;271 [<xref ref-type="bibr" rid="B31">31</xref>], her-2/<italic>neu </italic>p654&#x02013;662 [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>], and CEA p571&#x02013;579 [<xref ref-type="bibr" rid="B34">34</xref>] either by ELISPOT assay or by intracellular cytokine staining. HLA analysis, ELISPOT, and intracellular cytokine staining were performed as previously described [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Positive responses were defined as previously described [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B30">30</xref>].</p></sec><sec><title>Survival analysis</title><p>First, we performed a Kaplan-Meier survival analysis comparing all T-cell-responders and all T-cell-non-responders. Additionally, a two-sided log rank test was used to test statistical significance. Then, in an attempt to reduce the influence of external factors, we compiled a patient group from non-responders matching them to responders according to the following criteria: UICC stage of disease, gender, presence of clinically detectable tumor at time of blood draw, duration of disease until blood draw, age at first diagnosis, and previous therapy. Survival in both groups was compared using Kaplan-Meier analysis and by a two-sided log rank test. A level of p &#x0003c; 0.05 was considered significant. SPSS (11.5) software was used.</p></sec></sec><sec><title>Results</title><sec><title>Patients, T cell response, survival of responders and non-responders</title><p>Fifty-four HLA-A2 positive CRC patients who had been analyzed for T cell responses were included in this study [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B30">30</xref>] and retrospectively analyzed for survival. The overall survival rate was 66.7% at a median of 27.5 months follow-up after blood draw for T cell analysis. In 16 out of 54 patients a total number of 26 T cell responses (between 10 and 1110 specific T cell per 10<sup>6 </sup>PBMC) against one of the three TAA Ep-CAM, her-2/<italic>neu</italic>, and CEA had been detected. Comparing all responders (n = 16) and all non-responders (n = 38), no survival difference was found in a two-sided log rank test (p = 0.4; Fig. <xref ref-type="fig" rid="F1">1A</xref>). A very slight trend toward better survival was found in favor of non-responders, which is, however, far from being statistically significant. Since we have previously observed that T cell responses occur more frequently in patients with advanced stages of disease, we compared clinical data for all patients; and found that among non-responders only 50% (19 out of 38) had clinical stage III or IV disease while 87.5% (14 out of 16) responding patients had stage III or IV disease. Thus, the data on survival are possibly based on a strong stage-related bias. Therefore, we subsequently used an approach matching non-responders to responders.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Kaplan-Meier survival analyses of colorectal cancer patients based on their T cell response state. Dashed lines refer to T-cell-responders, full lines refer to T-cell-non-responders, crosses mark censored cases. Time point 0 refers to the time of blood draw for T cell analysis. <bold>A</bold>. Two groups of CRC patients (total n = 54) were analyzed for survival after T cell analysis. One group had a spontaneous T cell response against the tumor associated antigens CEA, Ep-CAM, or her-2/neu (n = 16, dashed line). The other group had no T cell response against these antigens (n = 38, full line). No survival difference between the groups was found (log rank, p = 0.4). <bold>B</bold>. Two matched groups of CRC patients (total n = 32) were analyzed for survival after T cell analysis. One group had a spontaneous T cell response against tumor antigens CEA, Ep-CAM, or her-2/neu (n = 16, dashed line). The other group had no T cell response against these antigens and was selected by having similar clinical characteristics for stage, gender, presence of clinically detectable tumor at time of blood draw, duration of disease, age, and prior therapy (n = 16, full line). No survival difference was found (log rank, p = 0.7).</p></caption><graphic xlink:href="1479-5876-3-3-1"/></fig></sec><sec><title>Survival in matched patient groups</title><p>Sixteen patients from the above group of 38 non-responders were matched with 16 responders to obtain two groups comparable for potentially confounding clinical factors, in particular stage of disease (see table <xref ref-type="table" rid="T1">1</xref>). At the time of the survival analysis 13 of the total of 32 (40.6%) patients had died: seven T-cell-responders (n = 1 stage III, n = 6 stage IV) and six T-cell-non-responders (n = 1 stage III, n = 5 stage IV). All deaths were CRC-related. Median time to death among T-cell-responders was 11 months, among T-cell-non-responders 14.5 months. The calculated mean survival time after blood draw for patients without T cell response was 37.0 months (&#x000b1; 4.8 SEM) with a 95% confidence interval 27.5&#x02013;46.5. Mean survival of T-cell-responders was 40.2 months (&#x000b1; 6.5 SEM) with 95% confidence interval of 27.5&#x02013;52.9 (Fig. <xref ref-type="fig" rid="F1">1B</xref>). In a two-sided log rank test, survival did not show a statistically significant difference between responders and non-responders (p = 0.7). Of note, one to two years after blood draw, patients without T cell response had an up to 20% higher survival rate (approx. 80% vs. approx 60%). These results were, however, not significant. In a two-sided test with &#x003b2; = 0.2, a survival difference of 70% could have been considered significant at a level of &#x003b1; = 0.05 in a population of this size.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" colspan="2"><bold>Peripheral spontaneous T cell response against TAA</bold></td><td align="center"><bold>Positive</bold></td><td align="center"><bold>Negative (matched)</bold></td><td align="center"><bold>Negative (total)</bold></td></tr></thead><tbody><tr><td align="left" colspan="2">Number of patients</td><td align="center">16</td><td align="center">16</td><td align="center">38</td></tr><tr><td align="left" colspan="2">Age at first diagnosis, mean &#x000b1; SD</td><td align="center">61.2 &#x000b1; 12.1</td><td align="center">59.9 &#x000b1; 9.1</td><td align="center">60.8 &#x000b1; 11.1</td></tr><tr><td align="left" colspan="2">Male/Female</td><td align="center">11/5</td><td align="center">11/5</td><td align="center">19/19</td></tr><tr><td align="left" colspan="2">Duration of disease until T cell analysis (mean)</td><td align="center">31.8</td><td align="center">30.2</td><td align="center">27.4</td></tr><tr><td align="left">Stage (UICC)</td><td align="left">I</td><td align="center">0</td><td align="center">0</td><td align="center">1 (2.6%)</td></tr><tr><td></td><td align="left">II</td><td align="center">2 (12.5%)</td><td align="center">2 (12.5%)</td><td align="center">18 (47.4%)</td></tr><tr><td></td><td align="left">III</td><td align="center">3 (18.8%)</td><td align="center">3 (18.8%)</td><td align="center">5 (13.2%)</td></tr><tr><td></td><td align="left">IV</td><td align="center">11 (68.8%)</td><td align="center">11 (68.8%)</td><td align="center">14 (36.8%)</td></tr><tr><td align="left">Previous therapy</td><td align="left">CT</td><td align="center">9 (56.3%)</td><td align="center">12 (75%)</td><td align="center">18 (47.4%)</td></tr><tr><td></td><td align="left">RT</td><td align="center">3 (18.8%)</td><td align="center">4 (25%)</td><td align="center">7 (18.4%)</td></tr><tr><td></td><td align="left">Surgery</td><td align="center">12 (75%)</td><td align="center">14 (87.5%)</td><td align="center">30 (78.9%)</td></tr><tr><td align="left" colspan="2">Patients without evidence of tumor at time of blood draw</td><td align="center">4 (25%, 2 II, 2 III)</td><td align="center">4 (25%, 2 II, 2 III)</td><td align="center">17 (45%, 13 II, 3 III, 1 IV)</td></tr><tr><td align="left" colspan="2">Time from blood draw until death or last contact, mean &#x000b1; SD</td><td align="center">28.1 &#x000b1; 19.2</td><td align="center">27.4 &#x000b1; 15.0</td><td align="center">25.7 &#x000b1; 14.0</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: SD standard deviation, CT chemotherapy (5-FU + folic acid, in few cases plus Irinotecan), RT radiotherapy</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>In the present study, we analyzed the clinical course of colorectal cancer patients with or without T cells reactive against HLA-A2-binding epitopes of Ep-Cam, her-2/neu, and CEA. No survival difference between T-cell-responders and T-cell-non-responders was found. This result has to be interpreted cautiously due to the small number of HLA-A2+ patients responding to the above antigens. Obviously, these small numbers cause a high beta error. Thus, this study is only a first indication that the tested spontaneous T cell responses are not important prognostic factors for survival.</p><p>The second limitation of our study is that the known repertoire of TAA as potentially important T cell targets in CRC grows every year; and our T cell analysis included only a fraction of potential epitopes. Various other CRC-associated antigens, such as MUC1 or p53, and additional MHC class I antigenic epitopes of CEA and her2-neu have been described [summarized in [<xref ref-type="bibr" rid="B35">35</xref>]]. T cell responses against antigens in addition to the ones tested here could potentially play a role in immune surveillance of CRC.</p><p>Immune surveillance is understood as a complex process in which T cells and tumor cells influence each other in several ways ["immunoediting", [<xref ref-type="bibr" rid="B1">1</xref>]]. There are various potential factors related to tumor cells as well as T cells which may explain a lack of survival effect by TAA-specific T cells. The frequency of TAA-specific T cells detected in most patients was quite low in the range of 10 to 100 T cells per 10<sup>6 </sup>PBMC. These numbers may be too low to control tumor growth especially in patients with a higher tumor burden. Furthermore, a general T cell dysfunction including anergic T cells and T cells with downregulated CD3-zeta chains has been described in CRC patients [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. It is possible that the specific T cells detected in the present study are functionally unable to destroy tumor cells. This assumption, however, is not supported by our previous finding that TAA-specific T cells have an effector potential as analyzed in selected patients [<xref ref-type="bibr" rid="B11">11</xref>]. Since we have analyzed peripheral blood, we do not know if the circulating T cells have the potential to migrate to the tumor site or compartments where CRC cells frequently migrate to including lymph node, liver and bone marrow.</p><p>Furthermore, tumor cells may not be recognizable by TAA-specific T cells. It has been shown that CRC cell lines secrete immunosuppressive cytokines and that development of T cell responses is impeded due to low HLA expression and lack of intercellular adhesion molecule-1 (ICAM-1) and HLA-DR [<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B39">39</xref>]. This is especially relevant considering the fact that TAA-specific T cell responses in peripheral blood are more frequently detectable in advanced stages of CRC [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B40">40</xref>], as well as other tumors [<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. These data led to the hypothesis that metastasizing of tumor cells to lymph nodes is a prerequisite for the development of circulating T cell responses [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. Furthermore, the presence of TAA-directed T cell responses may have selected immune escape tumor variants. A broad variety of tumor escape mechanisms, such as antigen loss or loss of HLA expression, is described in various clinical conditions [<xref ref-type="bibr" rid="B43">43</xref>]. It is possible that we encounter similar mechanisms in the present study since malignant cells had grown <italic>in vivo </italic>during the presence of specific T cell responses. Finally, the role of suppressor and regulatory T cells in this specific context is unknown.</p><p>Taken together, no evidence was found that peripheral, spontaneous T cell responses against HLA-A*0201-binding epitopes of CEA, Ep-CAM, or her-2/neu influence survival of CRC patients. Since the low patient number limits the conclusion, further studies should investigate more patients, more detailed function and migratory pattern of spontaneous T cell responses as well as the genetic profile of the tumor; and consider a broader antigen and epitope repertoire. These studies could have implications for vaccination therapy as we learn more about why immune surveillance may fail to control tumors and if the presence of a natural T cell response may impact on the efficacy of a vaccine.</p></sec><sec><title>Abbreviations</title><p>CEA carcinoembryonic antigen, CRC, colorectal carcinoma; ELISPOT, enzyme-linked immunospot; IFN&#x003b3;, Interferon-&#x003b3;; HLA, human leukocyte antigen; PBMC, peripheral blood mononuclear cells, TAA, tumor associated antigen.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec></body><back><ack><sec><title>Acknowledgments</title><p>We thank Dr. Dr. W. Hopfenm&#x000fc;ller and Prof. Dr. P. Martus, both at the Institute for Medical Informatics, Biometry and Epidemiology, Charit&#x000e9; University Medicine Berlin, Germany, for statistical advice. Furthermore, we thank Orfea Zehm for excellent documentation and Sandra Bauer for excellent technical assistance.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Bruce</surname><given-names>AT</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>Cancer immunoediting: from immunosurveillance to tumor escape</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><fpage>991</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12407406</pub-id><pub-id pub-id-type="doi">10.1038/ni1102-991</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boon</surname><given-names>T</given-names></name><name><surname>van Baren</surname><given-names>N</given-names></name></person-group><article-title>Immunosurveillance against cancer and immunotherapy &#x02013; synergy or antagonism?</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>252</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12529468</pub-id><pub-id pub-id-type="doi">10.1056/NEJMe020165</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Shiiba</surname><given-names>K</given-names></name><name><surname>Ohuchi</surname><given-names>A</given-names></name><name><surname>Saigenji</surname><given-names>K</given-names></name><name><surname>Nagura</surname><given-names>H</given-names></name><name><surname>Ohtani</surname><given-names>H</given-names></name></person-group><article-title>CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>3491</fpage><lpage>3494</lpage><pub-id pub-id-type="pmid">9721846</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Massobrio</surname><given-names>M</given-names></name><name><surname>Regnani</surname><given-names>G</given-names></name><name><surname>Makrigiannakis</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>H</given-names></name><name><surname>Schlienger</surname><given-names>K</given-names></name><name><surname>Liebman</surname><given-names>MN</given-names></name><name><surname>Rubin</surname><given-names>SC</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name></person-group><article-title>Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">12529460</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa020177</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mihm</surname><given-names>M</given-names></name><name><surname>Clemente</surname><given-names>C</given-names></name><name><surname>Cascinelli</surname><given-names>N</given-names></name></person-group><article-title>Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response</article-title><source>Lab Investig</source><year>1996</year><volume>74</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">8569196</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>K</given-names></name><name><surname>Haensch</surname><given-names>W</given-names></name><name><surname>Roefzaad</surname><given-names>C</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name></person-group><article-title>Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3932</fpage><lpage>3936</lpage><pub-id pub-id-type="pmid">11358808</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ropponen</surname><given-names>KM</given-names></name><name><surname>Eskelinen</surname><given-names>MJ</given-names></name><name><surname>Lipponen</surname><given-names>PK</given-names></name><name><surname>Alhava</surname><given-names>E</given-names></name><name><surname>Kosma</surname><given-names>VM</given-names></name></person-group><article-title>Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer</article-title><source>J Pathol</source><year>1997</year><volume>182</volume><fpage>318</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">9349235</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199707)182:3&#x0003c;318::AID-PATH862&#x0003e;3.3.CO;2-Y</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oberg</surname><given-names>A</given-names></name><name><surname>Samii</surname><given-names>S</given-names></name><name><surname>Stenling</surname><given-names>R</given-names></name><name><surname>Lindmark</surname><given-names>G</given-names></name></person-group><article-title>Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors</article-title><source>Int J Colorectal Dis</source><year>2002</year><volume>17</volume><fpage>25</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12018450</pub-id><pub-id pub-id-type="doi">10.1007/s003840100337</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Funada</surname><given-names>Y</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Kikuchi</surname><given-names>R</given-names></name><name><surname>Takeno</surname><given-names>S</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Gabbert</surname><given-names>HE</given-names></name></person-group><article-title>Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer</article-title><source>Oncol Rep</source><year>2003</year><volume>10</volume><fpage>309</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12579264</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagorsen</surname><given-names>D</given-names></name><name><surname>Scheibenbogen</surname><given-names>C</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name><name><surname>Letsch</surname><given-names>A</given-names></name><name><surname>Keilholz</surname><given-names>U</given-names></name></person-group><article-title>Natural T cell immunity against cancer</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>4296</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">14555498</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagorsen</surname><given-names>D</given-names></name><name><surname>Keilholz</surname><given-names>U</given-names></name><name><surname>Rivoltini</surname><given-names>L</given-names></name><name><surname>Schmittel</surname><given-names>A</given-names></name><name><surname>Letsch</surname><given-names>A</given-names></name><name><surname>Asemissen</surname><given-names>AM</given-names></name><name><surname>Berger</surname><given-names>G</given-names></name><name><surname>Buhr</surname><given-names>HJ</given-names></name><name><surname>Thiel</surname><given-names>E</given-names></name><name><surname>Scheibenbogen</surname><given-names>C</given-names></name></person-group><article-title>Natural T cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>4850</fpage><lpage>4854</lpage><pub-id pub-id-type="pmid">10987297</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Valmori</surname><given-names>D</given-names></name><name><surname>Dunbar</surname><given-names>PR</given-names></name><name><surname>Speiser</surname><given-names>DE</given-names></name><name><surname>Lienard</surname><given-names>D</given-names></name><name><surname>Lejeune</surname><given-names>F</given-names></name><name><surname>Fleischhauer</surname><given-names>K</given-names></name><name><surname>Cerundolo</surname><given-names>V</given-names></name><name><surname>Cerottini</surname><given-names>JC</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name></person-group><article-title>High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals</article-title><source>J Exp Med</source><year>1999</year><volume>190</volume><fpage>705</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">10477554</pub-id><pub-id pub-id-type="doi">10.1084/jem.190.5.705</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>PP</given-names></name><name><surname>Yee</surname><given-names>C</given-names></name><name><surname>Savage</surname><given-names>PA</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name><name><surname>Brockstedt</surname><given-names>D</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Swetter</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><article-title>Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients</article-title><source>Nat Med</source><year>1999</year><volume>5</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">10371507</pub-id><pub-id pub-id-type="doi">10.1038/9525</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheibenbogen</surname><given-names>C</given-names></name><name><surname>Letsch</surname><given-names>A</given-names></name><name><surname>Thiel</surname><given-names>E</given-names></name><name><surname>Schmittel</surname><given-names>A</given-names></name><name><surname>Mailaender</surname><given-names>V</given-names></name><name><surname>Baerwolf</surname><given-names>S</given-names></name><name><surname>Nagorsen</surname><given-names>D</given-names></name><name><surname>Keilholz</surname><given-names>U</given-names></name></person-group><article-title>CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>2132</fpage><lpage>2137</lpage><pub-id pub-id-type="pmid">12200377</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-01-0163</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feuerer</surname><given-names>M</given-names></name><name><surname>Beckhove</surname><given-names>P</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Solomayer</surname><given-names>EF</given-names></name><name><surname>Bastert</surname><given-names>G</given-names></name><name><surname>Diel</surname><given-names>IJ</given-names></name><name><surname>Pedain</surname><given-names>C</given-names></name><name><surname>Oberniedermayr</surname><given-names>M</given-names></name><name><surname>Schirrmacher</surname><given-names>V</given-names></name><name><surname>Umansky</surname><given-names>V</given-names></name></person-group><article-title>Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>452</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">11283672</pub-id><pub-id pub-id-type="doi">10.1038/86523</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodolfo</surname><given-names>M</given-names></name><name><surname>Luksch</surname><given-names>R</given-names></name><name><surname>Stockert</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Collini</surname><given-names>P</given-names></name><name><surname>Ranzani</surname><given-names>T</given-names></name><name><surname>Lombardo</surname><given-names>C</given-names></name><name><surname>Dalerba</surname><given-names>P</given-names></name><name><surname>Rivoltini</surname><given-names>L</given-names></name><name><surname>Arienti</surname><given-names>F</given-names></name><name><surname>Fossati-Bellani</surname><given-names>F</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Parmiani</surname><given-names>G</given-names></name><name><surname>Castelli</surname><given-names>C</given-names></name></person-group><article-title>Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>6948</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">14583496</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>A</given-names></name><name><surname>Ferris</surname><given-names>R</given-names></name><name><surname>Whiteside</surname><given-names>T</given-names></name><name><surname>DeLeo</surname><given-names>A</given-names></name></person-group><article-title>Immune Responses to P53 in Patients with Cancer: Elevated Frequencies of Tetramer+ P53 Peptide-Specific T Cells and Regulatory CD4+CD25+ Cells at Tumor Sites Compared to the Peripheral Circulation</article-title><source>J Immunother</source><year>2003</year><volume>26</volume><comment>Abstract</comment></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karanikas</surname><given-names>V</given-names></name><name><surname>Colau</surname><given-names>D</given-names></name><name><surname>Baurain</surname><given-names>JF</given-names></name><name><surname>Chiari</surname><given-names>R</given-names></name><name><surname>Thonnard</surname><given-names>J</given-names></name><name><surname>Gutierrez-Roelens</surname><given-names>I</given-names></name><name><surname>Goffinet</surname><given-names>C</given-names></name><name><surname>Van Schaftingen</surname><given-names>EV</given-names></name><name><surname>Weynants</surname><given-names>P</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name><name><surname>Coulie</surname><given-names>PG</given-names></name></person-group><article-title>High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3718</fpage><lpage>3724</lpage><pub-id pub-id-type="pmid">11325844</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valmori</surname><given-names>D</given-names></name><name><surname>Scheibenbogen</surname><given-names>C</given-names></name><name><surname>Dutoit</surname><given-names>V</given-names></name><name><surname>Nagorsen</surname><given-names>D</given-names></name><name><surname>Asemissen</surname><given-names>AM</given-names></name><name><surname>Rubio-Godoy</surname><given-names>V</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><name><surname>Guillaume</surname><given-names>P</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Lipp</surname><given-names>M</given-names></name><name><surname>Dietrich</surname><given-names>PY</given-names></name><name><surname>Thiel</surname><given-names>E</given-names></name><name><surname>Cerottini</surname><given-names>JC</given-names></name><name><surname>Lienard</surname><given-names>D</given-names></name><name><surname>Keilholz</surname><given-names>U</given-names></name></person-group><article-title>Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting <italic>ex vivo </italic>tumor-specific cytolytic activity</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>1743</fpage><lpage>1750</lpage><pub-id pub-id-type="pmid">11912149</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Livingston</surname><given-names>PO</given-names></name><name><surname>Wong</surname><given-names>GY</given-names></name><name><surname>Adluri</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Padavan</surname><given-names>M</given-names></name><name><surname>Parente</surname><given-names>R</given-names></name><name><surname>Hanlon</surname><given-names>C</given-names></name><name><surname>Calves</surname><given-names>MJ</given-names></name><name><surname>Helling</surname><given-names>F</given-names></name><name><surname>Ritter</surname><given-names>G</given-names></name><name><surname>Oetten</surname><given-names>HF</given-names></name><name><surname>Lloyd</surname><given-names>JO</given-names></name></person-group><article-title>Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside</article-title><source>J Clin Oncol</source><year>1994</year><volume>12</volume><fpage>1036</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">8164027</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheibenbogen</surname><given-names>C</given-names></name><name><surname>Letsch</surname><given-names>A</given-names></name><name><surname>Schmittel</surname><given-names>A</given-names></name><name><surname>Asemissen</surname><given-names>AM</given-names></name><name><surname>Thiel</surname><given-names>E</given-names></name><name><surname>Keilholz</surname><given-names>U</given-names></name></person-group><article-title>Rational peptide-based tumour vaccine development and T cell monitoring</article-title><source>Seminars in Cancer biology</source><year>2003</year><volume>13</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">15001161</pub-id><pub-id pub-id-type="doi">10.1016/j.semcancer.2003.09.006</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name><name><surname>Dhodapkar</surname><given-names>M</given-names></name><name><surname>Burkeholder</surname><given-names>S</given-names></name><name><surname>Taquet</surname><given-names>N</given-names></name><name><surname>Rolland</surname><given-names>A</given-names></name><name><surname>Taquet</surname><given-names>S</given-names></name><name><surname>Coquery</surname><given-names>S</given-names></name><name><surname>Wittkowski</surname><given-names>KM</given-names></name><name><surname>Bhardwaj</surname><given-names>N</given-names></name><name><surname>Pineiro</surname><given-names>L</given-names></name><name><surname>Steinman</surname><given-names>R</given-names></name><name><surname>Fay</surname><given-names>J</given-names></name></person-group><article-title>Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>6451</fpage><lpage>6458</lpage><pub-id pub-id-type="pmid">11522640</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>L</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Rivas</surname><given-names>A</given-names></name><name><surname>Benike</surname><given-names>C</given-names></name><name><surname>Yuen</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>GA</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name><name><surname>Engleman</surname><given-names>EG</given-names></name></person-group><article-title>Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>8809</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">11427731</pub-id><pub-id pub-id-type="doi">10.1073/pnas.141226398</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coulie</surname><given-names>PG</given-names></name><name><surname>Karanikas</surname><given-names>V</given-names></name><name><surname>Colau</surname><given-names>D</given-names></name><name><surname>Lurquin</surname><given-names>C</given-names></name><name><surname>Landry</surname><given-names>C</given-names></name><name><surname>Marchand</surname><given-names>M</given-names></name><name><surname>Dorval</surname><given-names>T</given-names></name><name><surname>Brichard</surname><given-names>V</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name></person-group><article-title>A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>10290</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11517302</pub-id><pub-id pub-id-type="doi">10.1073/pnas.161260098</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belli</surname><given-names>F</given-names></name><name><surname>Testori</surname><given-names>A</given-names></name><name><surname>Rivoltini</surname><given-names>L</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Andreola</surname><given-names>G</given-names></name><name><surname>Sertoli</surname><given-names>MR</given-names></name><name><surname>Gallino</surname><given-names>G</given-names></name><name><surname>Piris</surname><given-names>A</given-names></name><name><surname>Cattelan</surname><given-names>A</given-names></name><name><surname>Lazzari</surname><given-names>I</given-names></name><name><surname>Carrabba</surname><given-names>M</given-names></name><name><surname>Scita</surname><given-names>G</given-names></name><name><surname>Santantonio</surname><given-names>C</given-names></name><name><surname>Pilla</surname><given-names>L</given-names></name><name><surname>Tragni</surname><given-names>G</given-names></name><name><surname>Lombardo</surname><given-names>C</given-names></name><name><surname>Arienti</surname><given-names>F</given-names></name><name><surname>Marchiano</surname><given-names>A</given-names></name><name><surname>Queirolo</surname><given-names>P</given-names></name><name><surname>Bertolini</surname><given-names>F</given-names></name><name><surname>Cova</surname><given-names>A</given-names></name><name><surname>Lamaj</surname><given-names>E</given-names></name><name><surname>Ascani</surname><given-names>L</given-names></name><name><surname>Camerini</surname><given-names>R</given-names></name><name><surname>Corsi</surname><given-names>M</given-names></name><name><surname>Cascinelli</surname><given-names>N</given-names></name><name><surname>Lewis</surname><given-names>JJ</given-names></name><name><surname>Srivastava</surname><given-names>P</given-names></name><name><surname>Parmiani</surname><given-names>G</given-names></name></person-group><article-title>Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>4169</fpage><lpage>4180</lpage><pub-id pub-id-type="pmid">12377960</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2002.09.134</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Bade</surname><given-names>E</given-names></name><name><surname>Kuniyoshi</surname><given-names>C</given-names></name><name><surname>Spears</surname><given-names>L</given-names></name><name><surname>Jeffery</surname><given-names>G</given-names></name><name><surname>Marty</surname><given-names>V</given-names></name><name><surname>Groshen</surname><given-names>S</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name></person-group><article-title>Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><fpage>2756</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">10537339</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slingluff</surname><given-names>CL</given-names><suffix>Jr</suffix></name><name><surname>Yamshchikov</surname><given-names>G</given-names></name><name><surname>Neese</surname><given-names>P</given-names></name><name><surname>Galavotti</surname><given-names>H</given-names></name><name><surname>Eastham</surname><given-names>S</given-names></name><name><surname>Engelhard</surname><given-names>VH</given-names></name><name><surname>Kittlesen</surname><given-names>D</given-names></name><name><surname>Deacon</surname><given-names>D</given-names></name><name><surname>Hibbitts</surname><given-names>S</given-names></name><name><surname>Grosh</surname><given-names>WW</given-names></name><name><surname>Petroni</surname><given-names>G</given-names></name><name><surname>Cohen</surname><given-names>R</given-names></name><name><surname>Wiernasz</surname><given-names>C</given-names></name><name><surname>Patterson</surname><given-names>JW</given-names></name><name><surname>Conway</surname><given-names>BP</given-names></name><name><surname>Ross</surname><given-names>WG</given-names></name></person-group><article-title>Phase I trial of a melanoma vaccine with gp100(280&#x02013;288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes</article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><fpage>3012</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">11595689</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Kuniyoshi</surname><given-names>J</given-names></name><name><surname>Rubio</surname><given-names>V</given-names></name><name><surname>Stuges</surname><given-names>T</given-names></name><name><surname>Groshen</surname><given-names>S</given-names></name><name><surname>Gee</surname><given-names>C</given-names></name><name><surname>Lau</surname><given-names>R</given-names></name><name><surname>Jeffery</surname><given-names>G</given-names></name><name><surname>Margolin</surname><given-names>K</given-names></name><name><surname>Marty</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name></person-group><article-title>Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>3836</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">11559721</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>J</given-names></name><name><surname>Sondak</surname><given-names>VK</given-names></name><name><surname>Scotland</surname><given-names>R</given-names></name><name><surname>Phillip</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Rubio</surname><given-names>V</given-names></name><name><surname>Stuge</surname><given-names>TB</given-names></name><name><surname>Groshen</surname><given-names>SG</given-names></name><name><surname>Gee</surname><given-names>C</given-names></name><name><surname>Jeffery</surname><given-names>GG</given-names></name><name><surname>Sian</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>PP</given-names></name></person-group><article-title>Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma</article-title><source>Cancer</source><year>2003</year><volume>97</volume><fpage>186</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">12491520</pub-id><pub-id pub-id-type="doi">10.1002/cncr.11045</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagorsen</surname><given-names>D</given-names></name><name><surname>Scheibenbogen</surname><given-names>C</given-names></name><name><surname>Schaller</surname><given-names>G</given-names></name><name><surname>Leigh</surname><given-names>B</given-names></name><name><surname>Schmittel</surname><given-names>A</given-names></name><name><surname>Letsch</surname><given-names>A</given-names></name><name><surname>Thiel</surname><given-names>E</given-names></name><name><surname>Keilholz</surname><given-names>U</given-names></name></person-group><article-title>Differences in T cell immunity towards tumor associated antigens between colorectal cancer and breast cancer</article-title><source>Int J Cancer</source><year>2003</year><volume>105</volume><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">12673683</pub-id><pub-id pub-id-type="doi">10.1002/ijc.11052</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ras</surname><given-names>E</given-names></name><name><surname>Burg</surname><given-names>SH</given-names></name><name><surname>van</surname><given-names>der</given-names></name><name><surname>Zegveld</surname><given-names>ST</given-names></name><name><surname>Brandt</surname><given-names>RMP</given-names></name><name><surname>Kuppen</surname><given-names>PJK</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>Warnarr</surname><given-names>SO</given-names></name><name><surname>Velde</surname><given-names>CJH</given-names></name><name><surname>van</surname><given-names>de</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name></person-group><article-title>Identification of potential HLA-A 0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA)</article-title><source>Human Immunology</source><year>1997</year><volume>53</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">9127151</pub-id><pub-id pub-id-type="doi">10.1016/S0198-8859(97)00032-3</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peoples</surname><given-names>GE</given-names></name><name><surname>Goedegebuure</surname><given-names>PS</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Linehan</surname><given-names>DC</given-names></name><name><surname>Yoshino</surname><given-names>I</given-names></name><name><surname>Eberlein</surname><given-names>TJ</given-names></name></person-group><article-title>Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide</article-title><source>Proc Natl Acad Sci U S A</source><year>1995</year><volume>92</volume><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">7831305</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peiper</surname><given-names>M</given-names></name><name><surname>Goedegebuure</surname><given-names>PS</given-names></name><name><surname>Linehan</surname><given-names>DC</given-names></name><name><surname>Ganguly</surname><given-names>E</given-names></name><name><surname>Douville</surname><given-names>CC</given-names></name><name><surname>Eberlein</surname><given-names>TJ</given-names></name></person-group><article-title>The Her-2/neu-derived peptide p654&#x02013;662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes</article-title><source>Eur J Immunol</source><year>1997</year><volume>27</volume><fpage>1115</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">9174600</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>KY</given-names></name><name><surname>Zaremba</surname><given-names>S</given-names></name><name><surname>Nieroda</surname><given-names>CA</given-names></name><name><surname>Zhu</surname><given-names>MZ</given-names></name><name><surname>Hamilton</surname><given-names>JM</given-names></name><name><surname>Schlom</surname><given-names>J</given-names></name></person-group><article-title>Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine</article-title><source>J Natl Cancer Inst</source><year>1995</year><volume>87</volume><fpage>982</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">7629885</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Titu</surname><given-names>LV</given-names></name><name><surname>Monson</surname><given-names>JR</given-names></name><name><surname>Greenman</surname><given-names>J</given-names></name></person-group><article-title>The role of CD8(+) T cells in immune responses to colorectal cancer</article-title><source>Cancer Immunol Immunother</source><year>2002</year><volume>51</volume><fpage>235</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">12070710</pub-id><pub-id pub-id-type="doi">10.1007/s00262-002-0276-4</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pellegrini</surname><given-names>P</given-names></name><name><surname>Berghella</surname><given-names>AM</given-names></name><name><surname>Del Beato</surname><given-names>T</given-names></name><name><surname>Cicia</surname><given-names>S</given-names></name><name><surname>Adorno</surname><given-names>D</given-names></name><name><surname>Casciani</surname><given-names>CU</given-names></name></person-group><article-title>Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and nvolvement in cancer establishment and progression</article-title><source>Cancer Immunol Immunother</source><year>1996</year><volume>42</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8625361</pub-id><pub-id pub-id-type="doi">10.1007/s002620050244</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoong</surname><given-names>KF</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name></person-group><article-title>Interleukin 2 restores CD3-&#x003b6; chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>1072</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">9569042</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>JS</given-names></name><name><surname>Kammerer</surname><given-names>R</given-names></name><name><surname>Schultze</surname><given-names>H</given-names></name><name><surname>von Kleist</surname><given-names>S</given-names></name></person-group><article-title>Modulations of the effector function and cytokine production of human lymphocytes by secreted factors derived from colorectal-carcinoma cells</article-title><source>Int J Cancer</source><year>1997</year><volume>72</volume><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">9212235</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19970703)72:1&#x0003c;142::AID-IJC20&#x0003e;3.0.CO;2-K</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindauer</surname><given-names>M</given-names></name><name><surname>Rudy</surname><given-names>W</given-names></name><name><surname>Guckel</surname><given-names>B</given-names></name><name><surname>Doeberitz</surname><given-names>MV</given-names></name><name><surname>Meuer</surname><given-names>SC</given-names></name><name><surname>Moebius</surname><given-names>U</given-names></name></person-group><article-title>Gene transfer of costimulatory molecules into a human colorectal cancer cell line: requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity</article-title><source>Immunology</source><year>1998</year><volume>93</volume><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">9640250</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2567.1998.00450.x</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harashima</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Sasatomi</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Miyagi</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>A</given-names></name><name><surname>Tamura</surname><given-names>M</given-names></name><name><surname>Yamana</surname><given-names>H</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Shichijo</surname><given-names>S</given-names></name></person-group><article-title>Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases</article-title><source>Eur J Immunol</source><year>2001</year><volume>31</volume><fpage>323</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11180095</pub-id><pub-id pub-id-type="doi">10.1002/1521-4141(200102)31:2&#x0003c;323::AID-IMMU323&#x0003e;3.0.CO;2-0</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mortarini</surname><given-names>R</given-names></name><name><surname>Piris</surname><given-names>A</given-names></name><name><surname>Maurichi</surname><given-names>A</given-names></name><name><surname>Molla</surname><given-names>A</given-names></name><name><surname>Bersani</surname><given-names>I</given-names></name><name><surname>Bono</surname><given-names>A</given-names></name><name><surname>Bartoli</surname><given-names>C</given-names></name><name><surname>Santinami</surname><given-names>M</given-names></name><name><surname>Lombardo</surname><given-names>C</given-names></name><name><surname>Ravagnani</surname><given-names>F</given-names></name><name><surname>Cascinelli</surname><given-names>N</given-names></name><name><surname>Parmiani</surname><given-names>G</given-names></name><name><surname>Anichini</surname><given-names>A</given-names></name></person-group><article-title>Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>2535</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">12750277</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parmiani</surname><given-names>G</given-names></name><name><surname>Sensi</surname><given-names>M</given-names></name><name><surname>Castelli</surname><given-names>C</given-names></name><name><surname>Rivoltini</surname><given-names>L</given-names></name><name><surname>Anichini</surname><given-names>A</given-names></name></person-group><article-title>T-cell response to unique and shared antigens and vaccination of cancer patients</article-title><source>Cancer Immun</source><year>2002</year><volume>2</volume><fpage>6</fpage><pub-id pub-id-type="pmid">12747751</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marincola</surname><given-names>FM</given-names></name><name><surname>Jaffee</surname><given-names>EM</given-names></name><name><surname>Hicklin</surname><given-names>DJ</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name></person-group><article-title>Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance</article-title><source>Adv Immunol</source><year>2000</year><volume>74</volume><fpage>181</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">10605607</pub-id></citation></ref></ref-list></back></article>



